Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Caris Life Sciences (CAI) Shares Outstanding (Weighted Average) (2024 - 2025)

Caris Life Sciences (CAI) has 2 years of Shares Outstanding (Weighted Average) data on record, last reported at $167.2 million in Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 371.04% year-over-year to $167.2 million; the TTM value through Dec 2025 reached $167.2 million, up 371.04%, while the annual FY2025 figure was $167.2 million, 371.04% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $167.2 million in Q4 2025 per CAI's latest filing, down from $282.1 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $282.1 million in Q3 2025 and bottomed at $35.4 million in Q2 2024.